Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-706 monotherapy or combination therapy in advanced non-small cell lung cancer (Phase II, open-label, multi-center)
CTR20253459Phase 2Active
- Sponsor
- 3SBio
- Start
- Aug 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SSGJ-706 in non-small cell lung cancer (NSCLC), sponsored by 3SBio. Started Aug 2025; status: active.
02
Drugs
SSGJ-706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20253459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253459.